

United States Vaccine Market Report and Forecast 2024-2032

Market Report | 2023-12-18 | 160 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

United States Vaccine Market Report and Forecast 2024-2032

Market Outlook

According to the report by Expert Market Research (EMR), the United States vaccine market is projected to grow at a CAGR of 9.8% between 2024 and 2032. Aided by the technological advancements, an increasing focus on preventive healthcare, and a heightened awareness of infectious diseases, the market is expected to grow significantly by 2032.

Vaccines play a crucial role in public health, offering protection against various infectious diseases. In the United States, the vaccine market encompasses a broad range of products, including vaccines for influenza, pneumococcal disease, human papillomavirus (HPV), and a growing portfolio of vaccines for emerging infectious diseases. The demand for these vaccines is driven by a combination of government initiatives, public health campaigns, and a general increase in health consciousness among the populace.

The United States vaccine market outlook is being influenced by the well-established paediatric vaccination program. The routine immunisation schedule recommended by the Centres for Disease Control and Prevention (CDC) has ensured a steady demand for vaccines among children. The adult vaccine segment, though smaller, is also experiencing growth due to the increasing adoption of vaccines for shingles, pneumococcal disease, and HPV among others.

The market is also witnessing an expanding role of public-private partnerships and government funding in vaccine development and distribution. According to the United States vaccine market analysis, these collaborations are crucial in addressing public health needs, especially in the context of emerging infectious diseases and pandemic preparedness. The government's involvement in vaccine procurement and distribution, along with initiatives to ensure vaccine equity and accessibility, is a significant factor driving market growth.

Moreover, there is an increasing need for educational campaigns to address vaccine hesitancy, opening avenues for public health initiatives and collaborations which in turn is boosting the United States vaccine market demand. Moreover, advancements in vaccine storage and delivery systems, such as portable cold storage solutions, offer opportunities for innovation in the logistics and supply chain aspects of the market.

Another opportunity lies in the development of combination vaccines, which can protect against multiple diseases with a single shot. These vaccines are particularly appealing in paediatric immunisation, offering convenience and improved compliance.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Additionally, the growing interest in personalised vaccines, tailored to individual genetic profiles, presents a frontier for innovation and market expansion.

Market Segmentation

The market can be divided based on technology, indication, end use, and region.

Market Breakup by Technology

- Recombinant and Conjugate Vaccine
- Inactivated Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Others

Market Breakup by Indication

- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella, Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DPT)
- Polio
- Hepatitis
- Others

Market Breakup by End Use

- Paediatric Vaccine
- Adult Vaccine
- Travellers Vaccine

Market Breakup by Region

- New England
- Mideast
- Great Lakes
- Plains
- Southeast
- Southwest
- Rocky Mountain
- Far West

Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the United States vaccine market. Some of the major players explored in the report by Expert Market Research are as follows:

- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- AstraZeneca plc
- Johnson & Johnson Services, Inc.
- Others

About Us

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provides the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
- 2 Report Coverage - Key Segmentation and Scope
- 3 Report Description
 - 3.1 Market Definition and Outlook
 - 3.2 Properties and Applications
 - 3.3 Market Analysis
 - 3.4 Key Players
- 4 Key Assumptions
- 5 Executive Summary
 - 5.1 Overview
 - 5.2 Key Drivers
 - 5.3 Key Developments
 - 5.4 Competitive Structure
 - 5.5 Key Industrial Trends
- 6 Snapshot
 - 6.1 United States
- 7 Opportunities and Challenges in the Market
- 8 United States Vaccine Market Analysis
 - 8.1 Key Industry Highlights
 - 8.2 United States Vaccine Historical Market (2018-2023)
 - 8.3 United States Vaccine Market Forecast (2024-2032)
 - 8.4 United States Vaccine Market by Technology
 - 8.4.1 Recombinant and Conjugate Vaccine
 - 8.4.1.1 Historical Trend (2018-2023)
 - 8.4.1.2 Forecast Trend (2024-2032)
 - 8.4.2 Inactivated Vaccines
 - 8.4.2.1 Historical Trend (2018-2023)
 - 8.4.2.2 Forecast Trend (2024-2032)
 - 8.4.3 Live Attenuated Vaccines
 - 8.4.3.1 Historical Trend (2018-2023)
 - 8.4.3.2 Forecast Trend (2024-2032)
 - 8.4.4 Toxoid Vaccines
 - 8.4.4.1 Historical Trend (2018-2023)
 - 8.4.4.2 Forecast Trend (2024-2032)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.4.5 Others
- 8.5 United States Vaccine Market by Indication
 - 8.5.1 Pneumococcal Disease
 - 8.5.1.1 Historical Trend (2018-2023)
 - 8.5.1.2 Forecast Trend (2024-2032)
 - 8.5.2 Influenza
 - 8.5.2.1 Historical Trend (2018-2023)
 - 8.5.2.2 Forecast Trend (2024-2032)
 - 8.5.3 Human Papilloma Virus
 - 8.5.3.1 Historical Trend (2018-2023)
 - 8.5.3.2 Forecast Trend (2024-2032)
 - 8.5.4 Meningococcal Disease
 - 8.5.4.1 Historical Trend (2018-2023)
 - 8.5.4.2 Forecast Trend (2024-2032)
 - 8.5.5 Rotavirus
 - 8.5.5.1 Historical Trend (2018-2023)
 - 8.5.5.2 Forecast Trend (2024-2032)
 - 8.5.6 Varicella, Measles, Mumps, and Rubella
 - 8.5.6.1 Historical Trend (2018-2023)
 - 8.5.6.2 Forecast Trend (2024-2032)
 - 8.5.7 Diphtheria, Pertussis, and Tetanus (DPT)
 - 8.5.7.1 Historical Trend (2018-2023)
 - 8.5.7.2 Forecast Trend (2024-2032)
 - 8.5.8 Polio
 - 8.5.8.1 Historical Trend (2018-2023)
 - 8.5.8.2 Forecast Trend (2024-2032)
 - 8.5.9 Hepatitis
 - 8.5.9.1 Historical Trend (2018-2023)
 - 8.5.9.2 Forecast Trend (2024-2032)
 - 8.5.10 Others
- 8.6 United States Vaccine Market by End Use
 - 8.6.1 Paediatric Vaccine
 - 8.6.1.1 Historical Trend (2018-2023)
 - 8.6.1.2 Forecast Trend (2024-2032)
 - 8.6.2 Adult Vaccine
 - 8.6.2.1 Historical Trend (2018-2023)
 - 8.6.2.2 Forecast Trend (2024-2032)
 - 8.6.3 Travellers Vaccine
 - 8.6.3.1 Historical Trend (2018-2023)
 - 8.6.3.2 Forecast Trend (2024-2032)
- 8.7 United States Vaccine Market by Region
 - 8.7.1 New England
 - 8.7.2 Mideast
 - 8.7.3 Great Lakes
 - 8.7.4 Plains
 - 8.7.5 Southeast
 - 8.7.6 Southwest

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.7.7 Rocky Mountain
- 8.7.8 Far West
- 9 Regional Analysis
 - 9.1 New England
 - 9.1.1 Historical Trend (2018-2023)
 - 9.1.2 Forecast Trend (2024-2032)
 - 9.2 Mideast
 - 9.2.1 Historical Trend (2018-2023)
 - 9.2.2 Forecast Trend (2024-2032)
 - 9.3 Great Lakes
 - 9.3.1 Historical Trend (2018-2023)
 - 9.3.2 Forecast Trend (2024-2032)
 - 9.4 Plains
 - 9.4.1 Historical Trend (2018-2023)
 - 9.4.2 Forecast Trend (2024-2032)
 - 9.5 Southeast
 - 9.5.1 Historical Trend (2018-2023)
 - 9.5.2 Forecast Trend (2024-2032)
 - 9.6 Southwest
 - 9.6.1 Historical Trend (2018-2023)
 - 9.6.2 Forecast Trend (2024-2032)
 - 9.7 Rocky Mountain
 - 9.7.1 Historical Trend (2018-2023)
 - 9.7.2 Forecast Trend (2024-2032)
 - 9.8 Far West
 - 9.8.1 Historical Trend (2018-2023)
 - 9.8.2 Forecast Trend (2024-2032)
- 10 Market Dynamics
 - 10.1 SWOT Analysis
 - 10.1.1 Strengths
 - 10.1.2 Weaknesses
 - 10.1.3 Opportunities
 - 10.1.4 Threats
 - 10.2 Porter's Five Forces Analysis
 - 10.2.1 Supplier's Power
 - 10.2.2 Buyer's Power
 - 10.2.3 Threat of New Entrants
 - 10.2.4 Degree of Rivalry
 - 10.2.5 Threat of Substitutes
 - 10.3 Key Indicators for Demand
 - 10.4 Key Indicators for Price
- 11 Value Chain Analysis
- 12 Competitive Landscape
 - 12.1 Market Structure
 - 12.2 Company Profiles
 - 12.2.1 GlaxoSmithKline plc
 - 12.2.1.1 Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.1.2 Product Portfolio
- 12.2.1.3 Demographic Reach and Achievements
- 12.2.1.4 Certifications
- 12.2.2 Merck & Co., Inc.
 - 12.2.2.1 Company Overview
 - 12.2.2.2 Product Portfolio
 - 12.2.2.3 Demographic Reach and Achievements
 - 12.2.2.4 Certifications
- 12.2.3 Novartis AG
 - 12.2.3.1 Company Overview
 - 12.2.3.2 Product Portfolio
 - 12.2.3.3 Demographic Reach and Achievements
 - 12.2.3.4 Certifications
- 12.2.4 Pfizer Inc.
 - 12.2.4.1 Company Overview
 - 12.2.4.2 Product Portfolio
 - 12.2.4.3 Demographic Reach and Achievements
 - 12.2.4.4 Certifications
- 12.2.5 Sanofi
 - 12.2.5.1 Company Overview
 - 12.2.5.2 Product Portfolio
 - 12.2.5.3 Demographic Reach and Achievements
 - 12.2.5.4 Certifications
- 12.2.6 AstraZeneca plc
 - 12.2.6.1 Company Overview
 - 12.2.6.2 Product Portfolio
 - 12.2.6.3 Demographic Reach and Achievements
 - 12.2.6.4 Certifications
- 12.2.7 Johnson & Johnson Services, Inc.
 - 12.2.7.1 Company Overview
 - 12.2.7.2 Product Portfolio
 - 12.2.7.3 Demographic Reach and Achievements
 - 12.2.7.4 Certifications
- 12.2.8 Others

13 Key Trends and Developments in the Market

List of Key Figures and Tables

1. Market: Key Industry Highlights, 2018 and 2032
2. United States Vaccine Historical Market: Breakup by Technology (USD Million), 2018-2023
3. United States Vaccine Market Forecast: Breakup by Technology (USD Million), 2024-2032
4. United States Vaccine Historical Market: Breakup by Indication (USD Million), 2018-2023
5. United States Vaccine Market Forecast: Breakup by Indication (USD Million), 2024-2032
6. United States Vaccine Historical Market: Breakup by End Use (USD Million), 2018-2023
7. United States Vaccine Market Forecast: Breakup by End Use (USD Million), 2024-2032
8. United States Vaccine Historical Market: Breakup by Region (USD Million), 2018-2023
9. United States Vaccine Market Forecast: Breakup by Region (USD Million), 2024-2032
10. United States Vaccine Market Structure

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

United States Vaccine Market Report and Forecast 2024-2032

Market Report | 2023-12-18 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com